Chris Hurt

University of Southampton — United Kingdom

Agricultural and Biological Sciences · Life Sciences

35h-index4.2kcitations417works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Agricultural Economics and Policy(76), Esophageal Cancer Research and Treatment(48), Gastric Cancer Management and Outcomes(32), Pancreatic and Hepatic Oncology Research(29), Economics of Agriculture and Food Markets(26)

Publications415 total

Correlation between imaging-detected and pathological extranodal extension in a randomised trial in Human Papillomavirus-positive oropharyngeal cancer
British Journal of Cancer·2025· 1 citedOpen Access
ColoCap: determining the diagnostic accuracy of colon capsule endoscopy compared with standard colonoscopy in patients at risk of colorectal disease – a study protocol
BMJ Open·2025· 1 citedOpen Access
Reflection on Transoral Robotic Surgery vs Transoral Laser Microsurgery in HPV-Positive Oropharyngeal Squamous Cell Carcinoma—Reply
JAMA Otolaryngology–Head & Neck Surgery·2025
A single arm phase II trial of trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER.
Journal of Clinical Oncology·2025· 1 cited
Understanding the variation of modern endoscopic ultrasound use in patients with oesophageal cancer (VALUE): protocol for a multi-methods study
BJR|Open·2024Open Access
Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?
Clinical Oncology·2024Open Access
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
BMC Cancer·2024· 2 citedOpen Access
Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma
JAMA Otolaryngology–Head & Neck Surgery·2024· 12 citedOpen Access
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial
European Journal of Cancer·2024· 5 citedOpen Access
499TiP A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN PROGRESS)
Annals of Oncology·2024· 1 citedOpen Access
Aspiration Rates and Clinician-graded Dysphagia after Transoral Surgery (TOS): An Interim Analysis of Modified Barium Swallow (MBS) Studies (videofluoroscopy) from the PATHOS trial
International Journal of Radiation Oncology*Biology*Physics·2024
121 Differential functional outcomes following transoral surgery for oropharyngeal carcinoma -laser versus robot
Radiotherapy and Oncology·2024· 1 citedOpen Access
49 Development of a Normal Tissue Complication Probability Model for Dysphagia in PATHOS trial patients
Radiotherapy and Oncology·2024Open Access
Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV
UNC Libraries·2024Open Access
Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study
SSRN Electronic Journal·2024Open Access
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
EClinicalMedicine·2023· 9 citedOpen Access
BI06 Short sharp shock or slow burn: clinician perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy vs. 5-fluorouracil/calcipotriol ointment combination therapy
British Journal of Dermatology·2023· 2 citedOpen Access
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).
Journal of Clinical Oncology·2023
MO-0712 Compliance to the PATHOS swallowing OAR atlas and impact on predicted dysphagia for trial patients
Radiotherapy and Oncology·2023
OC-0103 SCOPE2 PET: continuing CisCap v switch to CarPac in PET non-responders on dCRT for esophageal cancer
Radiotherapy and Oncology·2023
page 1 of 21Next →

Frequent Co-authors

Gareth Griffiths(15), Somnath Mukherjee(13), John Staffurth(12), Tom Crosby(12), Tim Maughan(11), Stephen Falk(9), Simon Gollins(9), Lisette Nixon(9), T. Crosby(8), Ruby Ray(8), Jane Blazeby(7), Sarah Gwynne(7), M. Hawkins(7), John Bridgewater(6), Rajarshi Roy(6), George Joseph(6), Ross A. Abrams(5), Betty Kirkwood(5), Karen Edmond(5), Seth Owusu‐Agyei(5)